PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27643888-6	2016	All the 5 TNFalpha blockers achieved better ASAS20, ASAS40, ASAS5/6 and ASAS-PR responses than the placebo.	asas40	52-58	tumor necrosis factor	Homo sapiens	10-18	
24718959-9	2015	For AS patients, TNFalpha blockers showed better efficacy than placebo for BASDAI (effect size 1.00), BASFI (effect size 0.67) and ASAS40 response (OR 4.7).	asas40	131-137	tumor necrosis factor	Homo sapiens	17-25	
24623678-7	2014	The percentage of ASAS40 responders was 31.5% (62 of 197 patients) in the group receiving TNFalpha blockers versus 13.2% (26 of 197) in the control group (OR 2.99 [95% CI 1.80-4.99], P = 0.0002).	asas40	18-24	tumor necrosis factor	Homo sapiens	90-98	
24623678-8	2014	This effectiveness was more pronounced in the subgroup of patients with sacroiliitis identified on magnetic resonance imaging, with 46% of ASAS40 responders receiving TNFalpha blockers versus 15% of ASAS40 responders receiving usual care (OR 4.99 [95% CI 2.17-11.51]).	asas40	139-145	tumor necrosis factor	Homo sapiens	167-175